Hodgkin disease in children: Reduced tailored chemotherapy for stage I-II disease

Journal of Pediatric Hematology/Oncology

Volumn 18, Issue 1, 1996, Pages 76-80

  Yaniv, I ^a,b   Saab, A ^a   Cohen, I J ^a   Goshen, Y ^a   Loven, D ^a   Stark, B ^a   Tamary, H ^a   Zaizov, R ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Chemotherapy; Children; Hodgkin disease

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; HODGKIN DISEASE; HUMAN; MALE; MEDIASTINUM CANCER; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; MALE; NEOPLASM STAGING; PREDNISONE; PROCARBAZINE; PROSPECTIVE STUDIES; REMISSION INDUCTION; VINBLASTINE; VINCRISTINE;

EID: 0030070253     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199602000-00015     Document Type: Article

References (27)

1. Leventhal GB. Management of stage I-II Hodgkin disease in children. J Clin Oncol 1990;7:1123-4.
2. Tucker MA, Coleman CN, Cox RS, et al. Risk of second cancers after treatment for Hodgkin disease. N Engl J Med 1988;318:76-81.
3. Leibenhaut M, Hoppe R, Efron B, et al. Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin disease. J Clin Oncol 1989;7:81.
4. Mauch PM, Larson D, Osteen R, et al. Prognostic factors for positive surgical staging in patients with Hodgkin disease. J Clin Oncol 1990;8:257.
5. Donaldson S, Glatstein E, Vosti K. Bacterial infections in pediatric Hodgkin disease. Cancer 1990;41:1949.
6. Andrieu JM, Ifrah H, Payen C, et al. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation combined with MOPP chemotherapy for Hodgkin disease. J Clin Oncol 1990;8:1148.
7. Van Leeuwen F, Somers R, Taal B, et al. Increased risk of lung cancer, non-Hodgkin lymphoma and leukemia following Hodgkin disease. J Clin Oncol 1989;7:1046.
8. Kaldor J, Day N, Clarke A, et al. Leukemia following Hodgkin disease. N Engl J Med 1990;322:7.
9. Donaldson SS, Kaplan HS. Complications of treatment of Hodgkin disease in children. Cancer Treat Rep 1982;66:977-89.
10. Kaplan HS. Hodgkin disease, ed 2. Cambridge: Harvard University Press, 1980:548-97.
11. Hoppe RT, Coleman CN, Cox RS, et al. The management of stage I-II Hodgkin disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 1982;59:455-65.
12. Hellman S, Mauch PM. Role of radiation therapy in the treatment of Hodgkin disease. Cancer Treat Rep 1982;66:915-23.
13. Wiemik PH, Gustafson J, Schimpff CS, et al. Combined modality treatment of Hodgkin disease confined to lymph nodes. Results 8 years later. Am J Med 1979;67:183-93.
14. Timothy AR, Van Dyk J, Sutcliffe SB. Radiation therapy for Hodgkin disease. In: Selby P, McElwain TJ, eds. Hodgkin disease. Oxford: Blackwell Scientific, 1987.
15. Gehan EA, Sulivan MP, Fuller LM, et al. The Intergroup Hodgkin disease in children study of stage I and II. Cancer 1990;65:1429-37.
16. DeVita VT Jr, Hubbard SM. Hodgkin disease. N Engl J Med 1993;328:560-5.
17. Biti GP, Cimino G, Cartoni C, et al. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin disease: eight-year update of an Italian prospective randomized study. J Clin Oncol 1992;10:378-82.
18. Longo DL, Glatstein E, Duffey PL, et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin disease: seven-year results of a prospective randomized trial. J Clin Oncot 1991;9:906-7.
19. Cimino G, Biti GP, Anselmo AP, et al. MOPP chemotherapy versus extended-field radiotherapy in the management of pathological stages I-IIA Hodgkin disease. J Clin Oncol 1980;7:732-7.
20. Maas PM. Controversies in the management of early stage Hodgkin disease. Blood 1994;2:318-29.
21. Donaldson S, Link MP. Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin disease. J Clin Oncol 1987;5:742-9.
22. Hunger PS, Link MP, Donaldson SS. ABVD/MOPP and low-dose involved field radiotherapy in pediatric Hodgkin disease. The Stanford experience.J Clin Oncol 1994;12:2160-6.
23. Hudson MM, Greenwald C, Thompson E, et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin disease. J Clin Oncol 1993;1:100-8.
24. Olweny CLM, Katongole-Mbidde E, Kiive E, et al. Childhood Hodgkin disease in Uganda: a 10-year experience. Cancer 1978;42:787-92.
25. Ekert H, Waters KD. Results of treatment of 18 children with Hodgkin disease with MOPP chemotherapy as the only treatment modality. Med Pediatr Oncol 1983;11:322-6.
26. Robinson B, Kingston J, Nogueira Costa R, et al. Chemotherapy and irradiation in childhood Hodgkin disease. Arch Dis Child 1984;59:1162-7.
27. Aviles A, Soto B, Guzman R, et al. Results of a randomized study of early stage Hodgkin disease using ABVD, EBVD or MBVD. Med Ped Oncol 1995;24:171-5.